Treatment of hypotension in preterm infants: pathophysiology versus evidence-based medicine

The association of cumulative vasoactive drugs and neurodevelopmental outcomes in preterm Infants <29 weeks gestation

OBJECTIVE

To assess the effect of cardiovascular medications on the neurodevelopment of preterm infants, as measured by calculated cumulative time of vasoactive-inotropic score (VISct).

METHODS

A retrospective study was conducted on preterm infants who developed significant hypotension defined as a mean BP more than 2SDs below the mean for GA and received treatment with duration > 6 hours for each hypotensive episode, we calculated the vasoactive inotropic score (VIS) and cumulative exposure to cardiovascular medications over time (VISct). The composite Bayley III was reported from the high-risk follow-up clinic for the surviving infants between 18 to 21 months corrected age.

RESULTS

VISct was significantly higher in infants with abnormal neurodevelopment. Cognitive Bayley was the most affected component with median (IQR) VISct 882.5(249,2047) versus 309(143,471) (p-value 0.012), followed by language function with VISct 786(261,1563.5), versus 343(106.75,473.75) (p-value 0.016) when those with Bayley III <85 were compared with those with normal Bayley IIIs.

CONCLUSION

High VISct scores may have negative effect on cognitive and language neurodevelopmental outcomes.

A vasoactive inotropic score predicts the severity of compromised systemic circulation and mortality in preterm infants

OBJECTIVE

To validate the vasoactive inotropic score as a predictor of the severity of compromised systemic circulation and mortality in preterm infants.

METHODS

A retrospective study was conducted on preterm infants with Compromised systemic circulation [hypotension±lactic acidosis±oliguria] who received a cardiovascular support, we calculated the vasoactive inotropic score (VIS) and cumulative exposure to cardiovascular medications over time (VISct). Receiver operator curve was constructed to predict the primary outcome which was death & refractory hypotension.

RESULTS

VIS had an area under the curve of 0.73 (95% CI 0.85-0.98, p <  0.001). A VIS cut off of 25 has sensitivity and specificity of 66% and 92%, and positive and negative predictive values of 78.5% and 83%, respectively.

CONCLUSION

High VIS predicts the severity of Compromised systemic circulation and mortality rate in preterm infants.

Hypotension in Preterm Infants (HIP) randomised trial

OBJECTIVE

To determine whether restricting the use of inotrope after diagnosis of low blood pressure (BP) in the first 72 hours of life affects survival without significant brain injury at 36 weeks of postmenstrual age (PMA) in infants born before 28 weeks of gestation.

DESIGN

Double-blind, placebo-controlled randomised trial. Caregivers were masked to group assignment.

SETTING

10 sites across Europe and Canada.

PARTICIPANTS

Infants born before 28 weeks of gestation were eligible if they had an invasive mean BP less than their gestational age that persisted for ≥15 min in the first 72 hours of life and a cerebral ultrasound free of significant (≥ grade 3) intraventricular haemorrhage.

INTERVENTION

Participants were randomly assigned to saline bolus followed by either a dopamine infusion (standard management) or placebo (5% dextrose) infusion (restrictive management).

PRIMARY OUTCOME

Survival to 36 weeks of PMA without severe brain injury.

RESULTS

The trial terminated early due to significant enrolment issues (7.7% of planned recruitment). 58 infants were enrolled between February 2015 and September 2017. The two groups were well matched for baseline variables. In the standard group, 18/29 (62%) achieved the primary outcome compared with 20/29 (69%) in the restrictive group (p=0.58). Additional treatments for low BP were used less frequently in the standard arm (11/29 (38%) vs 19/29 (66%), p=0.038).

CONCLUSION

Though this study lacked power, we did not detect major differences in clinical outcomes between standard or restrictive approach to treatment. These results will inform future studies in this area.

TRIAL REGISTRATION NUMBER

NCT01482559, EudraCT 2010-023988-17.